Incretin mimetics may act through the restoration of insulin signaling pathways, inducing further neuroprotective effects
[18] The NHS and NICE have incorporated this evidence into clinical guidance (NG28), recognising GLP-1 receptor agonists as valuable therapeutic options for patients with type 2 diabetes
are inventors on a patent application covering GLP-1 analogues described here
Carreau A, El Hafny-Rahbi B, Matejuk A, Grillon C, Kieda C
12,13 Multiple clinical trials have been launched to therapeutically target key oncogenic signaling pathways in drug-resistant cancers, underscoring the translational relevance of this axis (Table 2)
The article says a comprehensive medical evaluation covering blood glucose, lipids, kidney function and cardiovascular history should be conducted before any GLP-1 treatment begins during perimenopause